Cortexin vs P21

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Derived from CNTF; increases BDNF expression and promotes hippocampal neurogenesis; modulates PI3K/Akt pathway

P021 (also designated Peptide 6) is a synthetic tetrapeptide derived from the neurotrophic activity domain of ciliary neurotrophic factor (CNTF), developed to provide the neuroprotective and neurogenic actions of endogenous CNTF at small-molecule scale, with adamantane incorporation designed to improve oral bioavailability and CNS penetrance. It is proposed to upregulate BDNF and other neurotrophic factors through MAPK/ERK signaling pathways, promoting hippocampal neurogenesis, supporting synaptic plasticity, and reducing tau hyperphosphorylation in preclinical models of neurodegeneration. Rodent studies from the Iqbal laboratory at the NYS Institute for Basic Research have demonstrated that P021 improves learning and memory, promotes hippocampal neurogenesis, and reduces amyloid-β and tau pathological markers in transgenic mouse models of Alzheimer's disease. P021 is a research compound with no regulatory approval in any jurisdiction; all published evidence to date is from preclinical animal studies, and no human clinical trials have been registered or completed as of 2025. P21 as a CNTF-pathway peptide In the nootropic and cognitive peptide research context, P21 refers to a synthetic peptide analogue based on the ciliary neurotrophic factor (CNTF) receptor-binding domain, designed to activate CNTF signalling without the full-length protein's size limitations and potential inflammatory side effects associated with systemic CNTF administration. CNTF is a neuroprotective cytokine that promotes neuron survival, enhances BDNF production, and supports hippocampal plasticity — pathways relevant to learning, memory consolidation, and neuronal resilience. Research on P21 in rodent models has reported improved spatial learning and memory retention, reduced tau phosphorylation markers associated with neurodegeneration, and effects on hippocampal synaptic density. Clinical data is absent; all published evidence comes from preclinical animal studies. P21 is available as a research peptide from specialty vendors; it is not approved by any regulatory agency and has no established safety or dosing profile in humans. It is discussed within nootropic communities alongside semax, selank, and dihexa as a peptide with proposed neuroprotective and cognitive-enhancement mechanisms, though its evidence base is substantially thinner than those compounds.